key: cord-0977018-4v2pomr8 authors: Shimizu, Toshio; Kim, Dong‐Wan; Loong, Herbert H.; Lin, Chia‐Chi; Ng, Matthew CH; Yamamoto, Noboru; Ma, Brigette; Tan, Daniel SW title: Overcoming the impact of the COVID‐19 pandemic on oncology early phase trials and drug development in Asia—Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium date: 2021-01-27 journal: Asia Pac J Clin Oncol DOI: 10.1111/ajco.13510 sha: ba9d8f00d7d180f9b4b86d5a60a3103a01889d7f doc_id: 977018 cord_uid: 4v2pomr8 AIM: The significance and prioritization of early phase oncology trial continuation during a global pandemic is unknown. This study reported the outcomes, multiple challenges, and broad recommendations associated with the impact of the novel coronavirus disease 2019 (COVID‐19) on oncology early phase 1 trials—and on drug development in Asia—based on the experiences and perspectives of Asian oncology phase 1 centers. METHODS: Between March and April 2020 during the initial period of outbreak, the impact of COVID‐19 across oncology phase 1 sites in five Asian countries—China (Hong Kong), Japan, South Korea, Taiwan, and Singapore—was retrospectively analyzed. RESULTS: There was no trial termination or treatment discontinuation in all five countries. Although the most common impact was new patient enrollment being placed on hold, which was based on pharmaceutical sponsors’ decision‐making, the situation varied per site. Most sites had no restrictions in place that would limit their ability to fully comply with the requirements of conducting the early phase studies. The number of protocol deviations during the pandemic was largely dependent on domestic transportation status during the outbreak rather than the ability of the clinical trial centers. CONCLUSION: Determining the risk to benefits ratio of patients with cancer who are enrolled in early phase 1 clinical trials under the unusual circumstances of a global pandemic is important. Specific guidance or guidelines on the conduct of early phase 1 clinical trials during public health emergencies that are based on the recent lessons learned is urgently required. pandemic is important. Specific guidance or guidelines on the conduct of early phase 1 clinical trials during public health emergencies that are based on the recent lessons learned is urgently required. Asia, clinical trial, COVID-19, pandemic, phase 1 INTRODUCTION Coronavirus disease 2019 (COVID-19) has been rapidly spreading worldwide and was first identified as a public health emergency of major international concern and later declared a pandemic by the The impact of COVID-19 on phase 1 trials during the initial period of the pandemic across five phase 1 centers in Asia In Japan, on April 7, 2020, the government declared a state of emergency in response to the rapidly increasing numbers of COVID-19 pos- In Singapore, the first COVID-19 case was diagnosed on January 23, 2020 in a Chinese national from Wuhan who had traveled to Singapore three days earlier. The necessity of developing a multipronged strategy to address this emerging pandemic was identified, and a multi-ministry The Taiwanese As Since we especially focused on the impact of the COVID-19 pandemic on oncology phase 1 trials during the initial period of COVID-19 outbreak, March and April 2020 were selected as the study period for our investigation. It is important to point out several limitations of this study. In Korea, the first wave of the COVID-19 pandemic was almost controlled by March 2020, while in both Japan and Singapore, the disease did not surface until early April 2020. In Singapore, the 2020 Singapore circuit breaker (lockdown) measures were introduced by the government of Singapore during April 7, 2020 (2020-04-07)-June 1, 2020. In Japan, patients into ongoing studies as an approach to oncology early phase 1 trials during pandemic will be required for all of the described conditions to be met (Table 3) . Close communication with industry, sponsors, ethics, and health authorities Site has no restrictions in place that would limit ability to fully comply with the requirements of the conduct of the study. In particular, this would include site capability for participants enrolled to have all study-mandated procedures performed on-site including physical exams, tumor assessments, adverse event assessments, processing of biomarker and pharmacokinetic materials, as well as laboratory assessment and administration of trial product Guidance/policy • Guidance/policy in place that describes preventive measures against pandemic and required screening or clearances for safe participant visits to clinical trial sites. • Guidance/policy in place that describes the care for participants exposed to or infected with pathogen, after enrolment Determine that the benefits to the participant of enrolling in the clinical trial exceed the risks of trial participation in the unusual circumstances of pandemic Food & Drug Administration. FDA guidance on conduct of clinical trials of medical products during COVID-19 public health emergency Guidance for industry, investigators, and institutional review boards EMA guidance on the management of clinical trials during the COVID-19 (coronavirus) pandemic Adapting to a pandemic-conducting oncology trials during the SARS-CoV-2 pandemic Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease pandemic Virtually perfect? Telemedicine for COVID-19 Managing COVID-19 in the oncology clinic and avoiding the distraction effect A segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore Impact of the COVID-19 epidemic on a Pan-Asian academic oncology clinical trial The impact of COVID-19 on the conduct of clinical trials for medical products in Korea The impact of COVID-19 on clinical trial execution at the dana-farber cancer institute Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: findings from an Shimizu has a consultancy/advisory role for Takeda Oncology, and received research funding to his institution (outside the submitted work) from Novartis Hong Kong under the Consortium on Harmonization of Institutional Requirements for Clinical Research Kim received research funding to his institution (outside the submitted work) from Alpha Biopharma We thank Ms. Harumi Maruno, Ms. Miki Ito, Ms. Yoshiko Kanazu and Ms. Nobuko Ushirozawa at Clinical Trials Office, NCCH Japan, for data collection support. All authors equally contributed to the conception and design of the work; acquisition, analysis, and interpretation of data; drafting the work and revising it critically for important intellectual content; and provided approval of the final version to be published. The authors declare no conflict of interest. Toshio Shimizu https://orcid.org/0000-0001-6632-0638Matthew CH Ng https://orcid.org/0000-0003-3170-4126